Close

High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization Mar 12, 2024 11:55PM
High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization Mar 12, 2024 09:30PM
Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards Jan 24, 2024 12:00PM
Regeneron Commits $34 Million Over Five Years to Continue to Sponsor the Regeneron International Science and Engineering Fair (ISEF) Nov 13, 2023 09:00AM
Regeneron (REGN) and Intellia (NTLA) Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases Oct 3, 2023 07:02AM
View Older Stories

Oct 3, 2023 07:00AM Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases
Aug 9, 2023 07:32AM Regeneron (REGN) to Acquire Decibel Therapeutics (DBTX) for Over $4 Per Share
Aug 9, 2023 07:30AM Regeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss Programs
Aug 1, 2023 07:00AM Regeneron Announces the 2023 Winners of The Regeneron Prize for Creative Innovation
Jul 29, 2023 02:25PM Aflibercept 8 mg Two-Year Results from Pivotal PHOTON Trial in Diabetic Macular Edema Presented at ASRS
Jun 29, 2023 04:01PM Regeneron to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2023
Jun 27, 2023 02:46PM Regeneron (REGN) Announces Two-year Results for Aflibercept 8 mg from Pivotal PHOTON Trial Demonstrate Durable Vision Gains at Extended Dosing Intervals in Diabetic Macular Edema
Jun 27, 2023 02:46PM Two-year Results for Aflibercept 8 mg from Pivotal PHOTON Trial Demonstrate Durable Vision Gains at Extended Dosing Intervals in Diabetic Macular Edema
Jun 27, 2023 02:45PM Regeneron (REGN) Announces FDA Issues CRL for Aflibercept 8 mg Biologics License Application Solely Due to Ongoing Review of Inspection Findings at Third-party Filler
Jun 27, 2023 02:45PM FDA Issues Complete Response Letter (CRL) for Aflibercept 8 mg Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-party Filler
May 25, 2023 05:06PM Regeneron's (REGN) Updated Linvoseltamab Data Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple Myeloma
May 25, 2023 05:05PM Updated Linvoseltamab (BCMAxCD3) Data from Pivotal Trial Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple Myeloma
May 25, 2023 05:04PM Regeneron (REGN) Reports Fianlimab Combined with Libtayo Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations
May 25, 2023 05:00PM Fianlimab (LAG-3 inhibitor) Combined with Libtayo® (cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations
May 25, 2023 05:00PM Fianlimab (LAG-3 inhibitor) Combined with Libtayo® (cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations
May 21, 2023 02:18PM Dupixent® (dupilumab) Late-breaking Phase 3 COPD Results Presented at ATS and Simultaneously Published in the New England Journal of Medicine
May 19, 2023 03:32PM High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023
May 19, 2023 12:54PM High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023
May 18, 2023 04:01PM Regeneron Announces Investor Conference Presentations
May 18, 2023 11:45AM Regeneron Applauds Supreme Court’s Unanimous Opinion Striking Down Amgen’s PCSK9 Patent Claims and Supporting Scientific Innovation
May 4, 2023 06:30AM Regeneron Reports First Quarter 2023 Financial and Operating Results
May 2, 2023 07:00AM Regeneron to Highlight New and Updated Clinical Data at ASCO Showcasing Breadth of Cancer Research
May 2, 2023 07:00AM Regeneron to Highlight New and Updated Clinical Data at ASCO Showcasing Breadth of Cancer Research
Apr 26, 2023 04:05PM Regeneron (REGN) and Alnylam (ALNY) Report Positive Interim Phase 1 Clinical Data on ALN-APP
Apr 26, 2023 04:05PM Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Apr 26, 2023 04:05PM Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Apr 26, 2023 04:05PM Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Apr 17, 2023 07:32AM Regeneron (REGN) Announces Retirement of Board Chair
Apr 17, 2023 07:31AM Regeneron (REGN) Announces Retirement of Board Chair, Dr. P. Roy Vagelos, Accomplished Physician-Businessman and Industry Luminary
Apr 17, 2023 07:30AM Regeneron Announces Retirement of Board Chair, Dr. P. Roy Vagelos, Accomplished Physician-Businessman and Industry Luminary
Apr 17, 2023 07:30AM Regeneron Announces Retirement of Board Chair, Dr. P. Roy Vagelos, Accomplished Physician-Businessman and Industry Luminary
Apr 17, 2023 07:00AM Aflibercept 8 mg and EYLEA® (aflibercept) Injection Presentations at ARVO Provide New Insights into the Treatment of Serious Retinal Diseases
Apr 17, 2023 07:00AM Aflibercept 8 mg and EYLEA® (aflibercept) Injection Presentations at ARVO Provide New Insights into the Treatment of Serious Retinal Diseases
Apr 11, 2023 04:00PM Regeneron Announces Investor Conference Presentations
Apr 11, 2023 04:00PM Regeneron Announces Investor Conference Presentations
Apr 3, 2023 04:00PM Regeneron to Report First Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2023
Apr 3, 2023 04:00PM Regeneron to Report First Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2023
Mar 29, 2023 07:01AM Regeneron (REGN) Reports Libtayo in Combination with Chemotherapy Approved in EU as First-line Treatment of Advanced PD-L1 Positive NSCLC
Mar 29, 2023 07:00AM Libtayo® (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
Mar 29, 2023 07:00AM Libtayo® (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
Mar 28, 2023 07:31AM Regeneron (REGN), Sonoma Biotherapeutics Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases
Mar 28, 2023 07:30AM Regeneron and Sonoma Biotherapeutics Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases
Mar 28, 2023 07:30AM Regeneron and Sonoma Biotherapeutics Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases
Mar 28, 2023 07:30AM Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases
Mar 23, 2023 05:29AM Sanofi (SNY) and Regeneron (REGN) Report Dupixent Met Endpoints in Phase 3 Trial for COPD
Mar 23, 2023 02:00AM Press Release: Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial 
Mar 23, 2023 02:00AM Dupixent® (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal Trial
Mar 23, 2023 02:00AM Dupixent® (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal Trial
Mar 22, 2023 07:02AM Regeneron (REGN) Announces FDA Approval of Evkeeza
Mar 22, 2023 07:01AM Regeneron (REGN) Announces FDA Approves First-in-class Evkeeza for Young Children with Ultra-rare Form of High Cholesterol
View Older Stories